CONMED (CNMD) CEO Pat Beyer awarded $1M in RSUs vesting over 3 years
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Beyer Pat reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp President & CEO Pat Beyer received a grant of 28,145 RSUs, representing a $1 million target-value equity award. The RSUs are scheduled to vest over three years in three equal annual tranches starting April 1, 2026, with a two-year post-vest holding period on net after-tax shares. Following this grant, Beyer directly holds 28,145 RSUs tied to CONMED common stock, designed to align compensation with longer-term company performance.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Beyer Pat
Role
President & CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | RSUs (Restricted Stock Units) | 28,145 | $0.00 | -- |
Holdings After Transaction:
RSUs (Restricted Stock Units) — 28,145 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
RSU grant size: 28,145 RSUs
Target award value: $1M
Vesting schedule: 3 years, 3 equal annual tranches
+3 more
6 metrics
RSU grant size
28,145 RSUs
Grant to President & CEO Pat Beyer on April 1, 2026
Target award value
$1M
Additional equity award approved by Board for CEO
Vesting schedule
3 years, 3 equal annual tranches
Vesting begins April 1, 2026
Post-vest holding period
2 years
Applied to net after-tax shares after each vesting
RSU expiration
April 1, 2036
Expiration date of the RSUs reported
Shares following transaction
28,145 RSUs
Total RSUs held directly after grant
Key Terms
RSUs (Restricted Stock Units), target value, post-vest holding period, vest, +1 more
5 terms
RSUs (Restricted Stock Units) financial
"security_title: "RSUs (Restricted Stock Units)""
target value financial
"approved an additional equity award for the CEO of $1M in target value"
post-vest holding period financial
"with a 2-year post-vest holding period to be applied to net after tax shares"
vest financial
"scheduled to vest starting April 1st, 2026 over 3-years in three equal annual tranches"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
underlying security financial
"underlying_security_title: "Common Stock""
FAQ
What equity award did CONMED (CNMD) CEO Pat Beyer receive?
Pat Beyer received a grant of 28,145 restricted stock units (RSUs) tied to CONMED common stock. The award has a $1 million target value and is structured as part of the CEO’s equity-based compensation package approved by the company’s Board of Directors.
How will the new RSU grant for CONMED (CNMD) CEO vest?
The 28,145 RSUs granted to CONMED’s CEO are scheduled to vest over three years in three equal annual tranches starting April 1, 2026. This multi-year vesting schedule encourages retention and links realized compensation to the company’s performance over time.
Is there a holding requirement on CONMED (CNMD) CEO’s RSU award?
Yes. The RSU award carries a two-year post-vest holding period on net after-tax shares from each vesting event. This means shares that remain after taxes must be held for two additional years, reinforcing longer-term alignment between the CEO and shareholders.
What is the target value of CONMED (CNMD) CEO’s new RSU award?
The Board approved an additional equity award for the CEO with a $1 million target value. This value is delivered entirely in RSUs, which vest annually over three years starting April 1, 2026, subject to the time-based vesting and holding requirements described.
How many RSUs does CONMED (CNMD) CEO hold after this Form 4?
After this transaction, the Form 4 shows Pat Beyer holding 28,145 RSUs directly. These RSUs are convertible into the same number of CONMED common shares upon vesting and settlement, subject to the vesting schedule and post-vest holding requirements disclosed.